자유게시판

• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

ADHD Medication During Pregnancy and Breastfeeding

Women with ADHD face a difficult decision on whether to keep or stop taking ADHD medication during pregnancy and breast-feeding. There are few data regarding how exposure over time may affect a foetus.

A study recently published in Molecular Psychiatry demonstrates that children exposed to ADHD medication during pregnancy do not develop neurological disorders like hearing loss or vision, febrile seizures, or IQ impairment. The authors acknowledge that more high-quality studies are needed.

Risk/Benefit Analysis

Women who are pregnant and taking ADHD medications need to balance the benefits of using them against the risks to the fetus. Doctors don't have the necessary data to give clear guidelines, but they can provide information about the risks and benefits to help pregnant women make informed decisions.

A study published in Molecular Psychiatry found that women who were taking ADHD medications during early pregnancy did not have a significantly increased risk of fetal cardiac malformations or major structural birth defects. Researchers conducted a massive population-based case control study to examine the prevalence of structural defects that were major in infants who were born to mothers who took stimulants during pregnancy. Clinical geneticists, pediatric cardiologists and other experts looked over the cases to ensure that the classification was accurate and to eliminate any bias.

The research conducted by the researchers was not without limitations. In particular, they were not able to differentiate the effects of the medication from those of the disorder that is underlying. This limitation makes it difficult to determine whether the limited associations observed in the exposed groups are due to the use of medication or comorbidities that cause confusion. Additionally, the researchers did not look at the long-term effects of offspring on their parents.

The study did show that infants whose mothers took ADHD medication during pregnancy were at a more risk of being admitted to the neonatal intensive care unit (NICU) than those who whose mothers did not take any medication or cut back on their medications prior to or during pregnancy. This was due to central nervous system-related disorders, and the increased risk for admission did not appear to be influenced by the stimulant medications were used during pregnancy.

Women who were taking stimulant adhd sleep medication medications during pregnancy also had a higher chance of having an emergency caesarean section or having one whose baby scored low on the Apgar scale (less than 7). These increases did appear to be independent of the type of medication used during pregnancy.

The research suggests that the low risk associated with the use of ADHD medications during the early stages of pregnancy may be offset by the greater benefit to both mother and child of continued treatment for the woman's disorder. Physicians should speak with their patients about this and as much as possible, assist them develop coping skills that could reduce the impact of her disorder in her daily functioning and her relationships.

Medication Interactions

As more women than ever are being diagnosed with ADHD and being treated with medication, the issue of whether to keep or end treatment during pregnancy is one that doctors are having to face. These decisions are frequently made without clear and authoritative evidence. Instead, physicians must weigh their own knowledge, the experience of other physicians and the research that has been conducted on the subject.

Particularly, the issue of potential risks to the infant can be difficult. The research on this subject is based on observations rather than controlled studies, and the results are in conflict. In addition, most studies limit their analysis to live births, which can underestimate the severity of teratogenic effects that could result in abortion or termination of the pregnancy. The study discussed in this journal club addresses these limitations by analyzing data on live and deceased births.

The conclusion is that while some studies have found that there is a positive correlation between ADHD medications and the risk of certain birth defects, others have found no connection, and most studies have a neutral or slight negative effect. Therefore, a careful risk/benefit analysis is required in every situation.

It can be challenging, if not impossible, for women with ADHD to stop taking their medication. In a recent article published in the Archives of Women's Mental Health by psychologist Jennifer Russell, she notes that stopping ADHD medications during pregnancy can cause depression and feelings of loneliness. Furthermore, a loss of medication may affect the ability to complete job-related tasks and drive safely which are essential aspects of daily life for many people with ADHD.

She suggests women who are uncertain about whether to keep or discontinue medication due to their pregnancy, consider the possibility of educating friends, family members and colleagues on the condition, its effects on daily functioning, and the advantages of staying on the current treatment regimen. Educating them can also help the woman feel supported as she struggles with her decision. Certain medications can pass through the placenta. If the patient decides not to take her ADHD medication while breastfeeding, it is important to be aware that the medication could be passed on to her baby.

Risk of Birth Defects

As the use and misuse of ADHD medication to treat symptoms of attention deficit disorder hyperactivity disorder (ADHD) increases as does the concern about the possible effects of the drugs on fetuses. Recent research published in the journal Molecular Psychiatry has added to the body knowledge on this issue. Researchers used two massive datasets to analyze more than 4.3 million pregnancy and determine if the use of stimulant medications caused birth defects. Researchers discovered that, while the risk overall is low, first-trimester ADHD exposure to medication was associated with slightly higher risk of specific heart defects like ventriculoseptal defects.

The researchers of the study didn't find any association between the use of early medications and other congenital anomalies, like facial deformities or club feet. The findings are in line with previous studies that have shown the presence of a small, but significant increase in the risk of heart malformations in women who started taking ADHD medications prior to the time of the birth of their child. This risk increased during the latter part of pregnancy, as many women decide to stop taking their ADHD medications.

Women who took ADHD medication in the first trimester of their pregnancies were also more likely to have caesarean section, low Apgar score after delivery and a baby who required help breathing at birth. The researchers of the study could not remove bias in selection since they limited their study to women without other medical conditions that might have contributed to the findings.

The researchers hope that their research will aid in the clinical decisions of doctors who treat pregnant women. They advise that while the discussion of the benefits and risks is important but the decision to stop or maintain medication must be based on each woman's needs and the severity of her ADHD symptoms.

The authors also advise that, while stopping the medication is an option, it isn't a recommended practice because of the high rate of depression and other mental health issues in women who are pregnant or post-partum. Further, research shows that women who stop taking their medication will have a harder transitioning to life without them after the baby is born.

Nursing

It can be a stressful experience to become a mom. Women with ADHD who must work through their symptoms while attending physician appointments, getting ready for the arrival of their child and adapting to new routines in the home are often faced with a number of difficulties. Many women decide to continue taking their ADHD medication during pregnancy.

The majority of stimulant medications are absorbed by breast milk in small quantities, so the risk to breastfeeding infant is minimal. However, the amount of exposure to medications by the newborn may differ based on dosage, frequency it is administered, and the time of day it is administered. Additionally, different medications enter the body of the baby differently through the gastrointestinal tract as well as breast milk. The impact of this on a newborn isn't yet fully known.

Some physicians may discontinue stimulant medication during a woman's pregnancy due to the lack of research. This is a complicated decision for the patient, who must balance the benefits of continuing her medication with the potential risks to the fetus. Until more information is available, doctors should inquire with all pregnant patients about their experience with ADHD and if they are taking or planning to take medication during the perinatal period.

Numerous studies have proven that women can continue to take their Adhd medication Cost medication safely during pregnancy and breast-feeding. In response, an increasing number of patients are opting to do so. They have found through consultation with their doctors, that the benefits of retaining their current medication outweigh risk.

It is crucial for women suffering from ADHD who are contemplating breastfeeding to seek out a specialist psychiatrist's guidance prior to becoming pregnant. They should review their medications with their physician and discuss the pros and cons of continued treatment, including non-pharmacological strategies. Psychoeducation should also be offered to help women with ADHD be aware of their symptoms and the underlying disorder Learn about the available treatment options and reinforce existing strategies for coping. This should involve a multidisciplinary approach, which adhd medication is the best includes the GP as well as obstetricians, psychiatry and obstetricians. Pregnancy counselling should include the discussion of a treatment plan for both the mother and child, monitoring for signs of deterioration and when necessary, making adjustments to the medication regimen.